Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 16/20 | 0.72 |
| ▸ | MAOA | P21397 | 11/20 | 0.66 |
| ▸ | MAOB | P27338 | 11/20 | 0.66 |
| ▸ | RCOR1 | Q9UKL0 | 8/20 | 0.64 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17287948 | 1.00 | KDM1A (0.72) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL2561991 | 0.84 | NR1H4 (0.63) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL30816610 | 0.84 | NR1H4 (0.63) | KDM1AMAOAMAOBRCOR1KDM1B | |
| Hydrochloric Acid SCHEMBL26977347 | 0.83 | NR1H4 (0.62) | KDM1AMAOAMAOBRCOR1KDM1B | |
| Hydrochloric Acid SCHEMBL30745120 | 0.83 | NR1H4 (0.62) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL15780115 | 0.82 | EPHX2 (0.56) | KDM1AEPHX2 | |
| SCHEMBL2561238 | 0.80 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL30816679 | 0.80 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL30816658 | 0.79 | KMT2A (0.57) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL2563538 | 0.79 | KMT2A (0.57) | KDM1AMAOAMAOBRCOR1KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560949-B1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASE LSD1 AND/OR LSD2 | UNIVERSIT DEGLI STUDI DI ROMA LA SAPIENZA (IT) | 2015-12-02 | — | — | EP | claimed |
| US-8765820-B2 | Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2 | Universita Degli Studi Di Roma “La Sapienza” (IT) | 2014-07-01 | — | — | US | claimed |
| EP-2560949-A1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASE LSD1 AND/OR LSD2 | Università degli Studi di Roma "La Sapienza" (IT) | 2013-02-27 | — | — | EP | claimed |
| US-20130035377-A1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASES LSD1 AND/OR LSD2 | UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2013-02-07 | — | — | US | claimed |
| WO-2011131576-A1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASE LSD1 AND/OR LSD2 | UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2011-10-27 | — | — | WO | claimed |
| US-11918580-B2 | Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20210100800-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | INSTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-04-08 | — | — | US | disclosed |
| US-20180311245-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH CDK2 INHIBITORS IN THE TREATMENT OF CANCER | RASNA THERAPEUTICS LTD (GB) | 2018-11-01 | — | — | US | disclosed |
| WO-2018197583-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | ISTITUTO EUROPEO DI ONCOLOGIA (IT) | 2018-11-01 | — | — | WO | disclosed |
| WO-2017097865-A9 | COMBINATION OF CALORIC RESTRICTION (CR) OR IGF1/INSULIN RECEPTOR INHIBITOR WITH LSD1 INHIBITOR | ISTITUTO EUROPEO DI ONCOLOGIA (IT) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017097865-A1 | COMBINATION OF CALORIC RESTRICTION (CR) OR IGF1/INSULIN RECEPTOR INHIBITOR WITH LSD1 INHIBITOR | ISTITUTO EUROPEO DI ONCOLOGIA (IT) | 2017-06-15 | — | — | WO | disclosed |
| EP-2560949-B1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASE LSD1 AND/OR LSD2 | UNIVERSIT DEGLI STUDI DI ROMA LA SAPIENZA (IT) | 2015-12-02 | — | — | EP | disclosed |
| US-8765820-B2 | Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2 | Universita Degli Studi Di Roma “La Sapienza” (IT) | 2014-07-01 | — | — | US | disclosed |
| US-20130035377-A1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASES LSD1 AND/OR LSD2 | UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311245-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH CDK2 INHIBITORS IN THE TREATMENT OF CANCER | CDK2, EZH2, CDK6 | KDM1A 16/4885MAOA 1955/4885MAOB 1751/4885 |
| US-20210100800-A1 | USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | CDK6, KDM1B, KDM6B | KDM1A 7/4885MAOA 1440/4885MAOB 1514/4885 |
| US-20130035377-A1 | TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASES LSD1 AND/OR LSD2 | KDM1B, KDM2A, KDM3A | KDM1A 4/4885MAOA 103/4885MAOB 72/4885 |
| US-11918580-B2 | Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | CDK6, KDM1B, KDM6B | KDM1A 7/4885MAOA 1440/4885MAOB 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.